<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85444</article-id><article-id pub-id-type="doi">10.7554/eLife.85444</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>The Axin scaffold protects the kinase GSK3β from cross-pathway inhibition</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-75719"><name><surname>Gavagan</surname><given-names>Maire</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3986-6760</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-301856"><name><surname>Jameson</surname><given-names>Noel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9231-3765</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-140073"><name><surname>Zalatan</surname><given-names>Jesse G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1458-0654</contrib-id><email>zalatan@uw.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Department of Chemistry, University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Jura</surname><given-names>Natalia</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05t99sp05</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>07</day><month>08</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85444</elocation-id><history><date date-type="received" iso-8601-date="2022-12-08"><day>08</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-08-04"><day>04</day><month>08</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-12-06"><day>06</day><month>12</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.12.05.519208"/></event></pub-history><permissions><copyright-statement>© 2023, Gavagan et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Gavagan et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85444-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85444-figures-v2.pdf"/><abstract><p>Multiple signaling pathways regulate the kinase GSK3β by inhibitory phosphorylation at Ser9, which then occupies the GSK3β priming pocket and blocks substrate binding. Since this mechanism should affect GSK3β activity toward all primed substrates, it is unclear why Ser9 phosphorylation does not affect other GSK3β-dependent pathways, such as Wnt signaling. We used biochemical reconstitution and cell culture assays to evaluate how Wnt-associated GSK3β is insulated from cross-activation by other signals. We found that the Wnt-specific scaffold protein Axin allosterically protects GSK3β from phosphorylation at Ser9 by upstream kinases, which prevents accumulation of pS9-GSK3β in the Axin•GSK3β complex. Scaffold proteins that protect bound proteins from alternative pathway reactions could provide a general mechanism to insulate signaling pathways from improper crosstalk.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>GSK3β signaling</kwd><kwd>scaffold proteins</kwd><kwd>signaling crosstalk</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35 GM124773</award-id><principal-award-recipient><name><surname>Gavagan</surname><given-names>Maire</given-names></name><name><surname>Jameson</surname><given-names>Noel</given-names></name><name><surname>Zalatan</surname><given-names>Jesse G</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A biochemical approach using the Wnt pathway as a model system demonstrates a new mechanism for specificity in interconnected signaling networks through scaffold-mediated shielding of bound proteins.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Glycogen Synthase Kinase 3β (GSK3β) is a potential therapeutic target for a range of diseases (<xref ref-type="bibr" rid="bib3">Beurel et al., 2015</xref>; <xref ref-type="bibr" rid="bib31">Nusse and Clevers, 2017</xref>), but targeting GSK3β is complicated because it has important roles in multiple signaling pathways (<xref ref-type="bibr" rid="bib4">Bhat et al., 2018</xref>). Understanding how GSK3β is regulated by different signaling pathways could enable strategies to target distinct sub-populations of GSK3β.</p><p>Both Wnt and growth factor/insulin signaling pathways regulate GSK3β, but these pathways do not cross-activate (<xref ref-type="bibr" rid="bib12">Ding et al., 2000</xref>; <xref ref-type="bibr" rid="bib26">McManus et al., 2005</xref>; <xref ref-type="bibr" rid="bib29">Ng et al., 2009</xref>). In Wnt signaling, the scaffold protein Axin binds GSK3β, its substrate β-catenin, and other proteins in a Wnt-specific complex called the destruction complex. Wnt signals inhibit GSK3β phosphorylation of β-catenin (<xref ref-type="bibr" rid="bib21">Hernández et al., 2012</xref>; <xref ref-type="bibr" rid="bib36">Stamos et al., 2014</xref>), causing β-catenin levels to rise and activate downstream transcription (<xref ref-type="bibr" rid="bib31">Nusse and Clevers, 2017</xref>). Axin regulates kinase activity in the destruction complex, providing a mechanism to inhibit Wnt-associated GSK3β without affecting other GSK3β-dependent pathways (<xref ref-type="bibr" rid="bib3">Beurel et al., 2015</xref>; <xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). In contrast, in growth factor/insulin signaling, the kinases PKA and PKB/Akt phosphorylate GSK3β at Ser9 (<xref ref-type="bibr" rid="bib9">Cross et al., 1995</xref>; <xref ref-type="bibr" rid="bib13">Fang et al., 2000</xref>; <xref ref-type="bibr" rid="bib24">Jensen et al., 2007</xref>; <xref ref-type="bibr" rid="bib38">Sutherland et al., 1993</xref>), which inhibits GSK3β by binding in the priming pocket and blocking substrate binding (<xref ref-type="bibr" rid="bib10">Dajani et al., 2001</xref>; <xref ref-type="bibr" rid="bib15">Frame and Cohen, 2001</xref>; <xref ref-type="bibr" rid="bib36">Stamos et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">ter Haar et al., 2001</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). It remains unclear why growth factor/insulin signaling does not globally inhibit GSK3β and cross-activate the Wnt pathway.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Wnt signaling is insulated from signals that phosphorylate GSK3β at Ser9.</title><p>(<bold>A</bold>) In the Wnt pathway, the scaffold protein Axin coordinates a GSK3β complex that phosphorylates β-catenin, which is then degraded. Wnt signals inhibit phosphorylation, allowing β-catenin levels to rise and initiate a transcriptional program (<xref ref-type="bibr" rid="bib31">Nusse and Clevers, 2017</xref>). In other signaling pathways, upstream signals regulate GSK3β through phosphorylation at Ser9, which blocks substrate binding, inhibits activity toward downstream substrates, and activates downstream signaling (<xref ref-type="bibr" rid="bib39">Sutherland, 2011</xref>). (<bold>B</bold>) The scaffold protein Axin could insulate Wnt-associated GSK3β from Ser9 inhibition by restoring GSK3β activity toward β-catenin even when phosphorylated at Ser9 (Model 1) or by preventing accumulation of pS9-GSK3β in the Wnt destruction complex (Model 2).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig1-v2.tif"/></fig><p>Previous work in the field suggests two potential biochemical mechanisms that could insulate Wnt signaling from insulin and growth factor signals. First, by tethering GSK3β and the Wnt substrate β-catenin together, the Axin scaffold could rescue enzyme activity from the inhibitory effects of Ser9 phosphorylation (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="bibr" rid="bib3">Beurel et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Frame and Cohen, 2001</xref>). A second possibility is that Axin prevents accumulation of pS9-GSK3β, either through direct steric effects or indirect allosteric effects (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). This model is supported by in vivo experiments showing that in insulin-treated cells, Ser9 phosphorylation increases in the total GSK3β population but is unchanged in the Axin-associated GSK3β pool (<xref ref-type="bibr" rid="bib12">Ding et al., 2000</xref>; <xref ref-type="bibr" rid="bib29">Ng et al., 2009</xref>). Using a reconstituted biochemical system, we found that Axin allosterically protects GSK3β from phosphorylation at Ser9. The ability of scaffold proteins to allosterically regulate bound enzymes and substrates is well-established (<xref ref-type="bibr" rid="bib18">Good et al., 2011</xref>), but the use of similar mechanisms to prevent competing, scaffold-independent signaling reactions has not previously been characterized. Our findings suggest a new mechanism for how scaffold proteins can promote specificity in interconnected signaling networks by shielding bound proteins.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and Discussion</title><sec id="s2-1"><title>Phosphorylation at Ser9 inhibits GSK3β</title><p>It is well-established that Ser9 phosphorylation inhibits GSK3β activity, but quantitative measurements are limited and variable (<xref ref-type="bibr" rid="bib15">Frame and Cohen, 2001</xref>; <xref ref-type="bibr" rid="bib35">Stambolic and Woodgett, 1994</xref>; <xref ref-type="bibr" rid="bib38">Sutherland et al., 1993</xref>). To assess if the Wnt pathway can overcome Ser9 phosphorylation, we need quantitative metrics for comparison. We therefore used a biochemically reconstituted system to measure initial rates for the GSK3β reaction with pS45-β-catenin and determined the steady state kinetic parameters <italic>k</italic><sub>cat</sub>, <italic>K</italic><sub>M</sub>, and <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> as described previously (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). Comparing these parameters can distinguish whether Ser9 phosphorylation affects accumulation of the kinase-substrate complex or catalytic turnover. We used PKA to prepare fully-phosphorylated pS9-GSK3β (see Methods and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). We observed that phosphorylation of GSK3β at Ser9 decreases <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> toward pS45-β-catenin by a factor of ~200-fold compared with unphosphorylated or mutant S9A GSK3β (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The observed rates for unphosphorylated GSK3β and PKA-treated GSK3β_S9A are indistinguishable, indicating that the large rate decrease in pS9-GSK3β is from phosphorylation at Ser9, not any other unknown PKA phosphosites. pS9-GSK3β does not detectably saturate at high substrate concentration, giving a limit for the <italic>K</italic><sub>M</sub> of ≥2 μM. The &gt;sevenfold increase in <italic>K</italic><sub>M</sub> is consistent with the model that Ser9 phosphorylation inhibits GSK3β by interfering with substrate binding, although we cannot rule out the possibility that pSer9 also affects other catalytic steps.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Phosphorylation at Ser9 inhibits GSK3β activity toward pS45-β-catenin.</title><p>Kinetic scheme and Michaelis-Menten plots for reactions of unphosphorylated GSK3β, pS9-GSK3β, and GSK3β_S9A with pS45-β-catenin. Plots are <italic>V</italic><sub>obs</sub> versus [pS45-β-catenin] at 10 nM GSK3β. GSK3β phosphorylates pS45-β-catenin at three sites: S33, S37, and T41. Values are mean ± SD for at least three biological replicates. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref> for values of fitted kinetic parameters. See <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and D</xref> and <xref ref-type="fig" rid="fig2s9">Figure 2—figure supplement 9</xref> for characterization of GSK3β phosphorylation states and mutants.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Observed rates for data plotted in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85444-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Characterization of purified proteins.</title><p>(<bold>A</bold>) Coomassie-stained SDS-PAGE of purified proteins used in this work. All proteins except PKA were purified as MBP fusion proteins (see Materials and methods). Unphosphorylated GSK3β was purified after coexpression with lambda phosphatase (see Methods). pS45-β-catenin was purified after coexpression with CK1α as described previously (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). Phosphorylated GSK3β and GSK3β_S9A were purified after in vitro phosphorylation with PKA (see Materials and methods). Each lane was loaded with 10 μL of 4 μM protein. (<bold>B</bold>) Western blot for phosphorylation state of GSK3β at Ser9 and Tyr216. GSK3β samples are unphosphorylated GSK3β, pS9-GSK3β, GSK3β_S9A, and untreated GSK3β (unmodified recombinant protein, not coexpressed with lambda phosphatase or treated with PKA). After the western blot transfer, the membrane was cut down the center of the MW ladder lanes so each third of the membrane could be incubated with separate antibodies (α-pS9-GSK3β, α-MBP for total protein, and α-pY216-GSK3β). The membrane fragments were placed back together for imaging. (<bold>C</bold>) PKA phosphorylates GSK3β at Ser9. The extent of Ser9 phosphorylation was quantified by western blot (B). Fluorescence values were normalized using the α-MBP total protein loading control. No significant phosphorylation at Ser9 was detected for unphosphorylated GSK3β (phosphatase-treated) or GSK3β_S9A. Untreated GSK3β is partially (~10%) phosphorylated at Ser9. (<bold>D</bold>) Recombinant GSK3β is phosphorylated at Tyr216. The extent of Tyr216 phosphorylation was quantified by western blot (B). Fluorescence values were normalized using the α-MBP total protein loading control.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Coomassie-stained SDS-PAGE gel of purified proteins.</title><p>Coomassie-stained SDS-PAGE of purified proteins used in this work. All proteins except PKA were purified as MBP fusion proteins (see Materials and methods). Unphosphorylated GSK3β was purified after coexpression with lambda phosphatase (see Materials and methods). pS45-β-catenin was purified after coexpression with CK1α as described previously (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). Phosphorylated GSK3β and GSK3β_S9A were purified after in vitro phosphorylation with PKA (see Materials and methods). Each lane was loaded with 10 μL of 4 μM protein.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig2-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Western blot for phosphorylation state of GSK3β at Ser9 and Tyr216.</title><p>Western blot for phosphorylation state of GSK3β at Ser9 and Tyr216. GSK3β samples are unphosphorylated GSK3β, pS9-GSK3β, GSK3β_S9A, and untreated GSK3β (unmodified recombinant protein, not coexpressed with lambda phosphatase or treated with PKA). After the western blot transfer, the membrane was cut down the center of the MW ladder lanes so each third of the membrane could be incubated with separate antibodies (α-pS9-GSK3β, α-MBP for total protein, and α-pY216-GSK3β). The membrane fragments were placed back together for imaging.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig2-figsupp1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Protein phosphorylation kinetic assays.</title><p>(<bold>A</bold>) Representative western blots for reactions of GSK3β with pS45-β-catenin, PKA with GSK3β, and PKA with CREB<sub>127-135</sub>. Reactions were conducted with 10 nM GSK3β or 20 nM PKA and the substrate concentrations indicated. Each gel was cut before transferring to the membrane to facilitate multiple simultaneous transfers in the same apparatus (as seen in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>, <xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6</xref>, and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). The images shown are the complete, uncropped blot membrane images. (<bold>B</bold>) Timecourses of phosphorylation of endpoint standards for GSK3β-phosphorylated pS33/pS37/pT41-β-catenin, PKA-phosphorylated pS9-GSK3β, and PKA-phosphorylated pS133-CREB<sub>127-135</sub>. (<bold>C</bold>) The antibody signals are linear over a broad range spanning the observed signal in kinetic assays. The pS33/pS37/pT41-β-catenin data shows serial dilutions from a reaction timepoint with 3 µM pS45-β-catenin, 20 nM GSK3β and 500 nM miniAxin. The reaction was quenched at 1.5 min, which produces ~500 nM pS33/pS37/pT41-β-catenin. The quenched timepoint was diluted 1:5, then a set of twofold serial dilutions was loaded on the gel. The signal is linear over a concentration range of at least 1.5–100 nM. These data were published previously (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). The pS9-GSK3β and pS133-CREB127-135 plots show sets of twofold serial dilutions from a 1:4 dilution of pS9-GSK3β endpoint (PKA reactions with GSK3β) or undiluted endpoint (PKA reactions with CREB127-135), respectively. The pS9-GSK3β signal is linear over a range of at least 0.2–12.5 nM. The CREB127-135 signal is linear over a range of at least 1–50 nM.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Representative western blots for the reaction of pS9-GSK3β with pS45-β-catenin in the presence and absence of Axin.</title><p>Western blots for reactions of varying concentrations of pS45-β-catenin with 10 nM pS9-GSK3β in the presence and absence of 500 nM Axin. All gel samples were diluted 1:5 to prevent a gel smearing artifact (see Materials and methods).</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig2-figsupp2-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata2"><label>Figure 2—figure supplement 2—source data 2.</label><caption><title>Representative western blots for the reaction of PKA with GSK3β in the presence and absence of Axin.</title><p>Western blots for reactions of varying concentrations of GSK3β with 20 nM PKA +/-500 nM Axin. 500 nM GSK3β reaction gel samples without Axin were diluted 1:4 to prevent overloading the gel; all other reactions were diluted 1:2 (see Materials and methods).</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig2-figsupp2-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2s2sdata3"><label>Figure 2—figure supplement 2—source data 3.</label><caption><title>Representative western blots for the reaction of PKA with CREB<sub>127-135</sub> in the presence and absence of Axin.</title><p>Western blots for reactions of varying concentrations of CREB<sub>127-135</sub> with 20 nM PKA in the presence and absence of 500 nM Axin.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig2-figsupp2-data3-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>The concentration of ATP used for quantitative kinetic experiments (100 μM) is saturating for all reactions.</title><p>(<bold>A</bold>) Michaelis-Menten plot of V<sub>obs</sub> vs. [ATP] at 10 nM unphosphorylated GSK3β and 50 nM pS45-β-catenin in the presence and absence of 500 nM Axin. Fits to the Michaelis-Menten equation give <italic>K</italic><sub>M, ATP</sub> values of 4.6±0.9 μM and 3.7±1.3 μM in the presence and absence of Axin, respectively. (<bold>B</bold>) Michaelis-Menten plot of V<sub>obs</sub> vs. [ATP] at 20 nM PKA and 20 nM GSK3β in the presence and absence of 500 nM Axin. Fits to the Michaelis-Menten equation give <italic>K</italic><sub>M, ATP</sub> values of 3.0±0.6 μM and 3.3±0.8 μM in the presence and absence of Axin, respectively. (<bold>C</bold>) Michaelis-Menten plot of V<sub>obs</sub> vs. [ATP] at 20 nM PKA and 20 nM CREB<sub>127-135</sub> in the presence and absence of 500 nM Axin. Fits to the Michaelis-Menten equation give <italic>K</italic><sub>M, ATP</sub> values of 2.1±0.4 μM and 2.1±0.2 μM in the presence and absence of Axin, respectively. <italic>K</italic><sub>M</sub> values for (<bold>A</bold>)-(<bold>C</bold>) are compiled in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig2-figsupp3-v2.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Representative western blots for the reaction of unphosphorylated GSK3β with pS45-β-catenin in the presence and absence of Axin.</title><p>Western blots for reactions of varying concentrations of pS45-β-catenin with 10 nM GSK3β in the presence and absence of 500 nM Axin. All gel samples were diluted 1:5 to prevent a gel smearing artifact (see Materials and methods). See <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5</xref> for quantification.</p><p><supplementary-material id="fig2s4sdata1"><label>Figure 2—figure supplement 4—source data 1.</label><caption><title>Representative western blots for the reaction of unphosphorylated GSK3β with pS45-β-catenin in the presence and absence of Axin.</title><p>Western blots for reactions of varying concentrations of pS45-β-catenin with 10 nM GSK3β in the presence and absence of 500 nM Axin. All gel samples were diluted 1:5 to prevent a gel smearing artifact (see Materials and methods).</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig2-figsupp4-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig2-figsupp4-v2.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>Plots of product vs. time for reaction of GSK3β with pS45-β-catenin in the presence and absence of Axin.</title><p>(<bold>A</bold>) Product vs. time plots for reactions of unphosphorylated GSK3β with pS45-β-catenin in the absence of Axin. (<bold>B</bold>) Product vs. time plots for reactions of GSK3β with pS45-β-catenin in the presence of 500 nM Axin. Data in (<bold>A</bold>) and (<bold>B</bold>) correspond to the reaction conditions and western blots shown in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig2-figsupp5-v2.tif"/></fig><fig id="fig2s6" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 6.</label><caption><title>Representative western blots for the reaction of pS9-GSK3β with pS45-β-catenin in the presence and absence of Axin.</title><p>Western blots for reactions of varying concentrations of pS45-β-catenin with 10 nM pS9-GSK3β in the presence and absence of 500 nM Axin. All gel samples were diluted 1:5 to prevent a gel smearing artifact (see Materials and methods). See <xref ref-type="fig" rid="fig2s7">Figure 2—figure supplement 7</xref> for quantification.</p><p><supplementary-material id="fig2s6sdata1"><label>Figure 2—figure supplement 6—source data 1.</label><caption><title>Representative western blots for the reaction of pS9-GSK3β with pS45-β-catenin in the presence and absence of Axin.</title><p>Western blots for reactions of varying concentrations of pS45-β-catenin with 10 nM pS9-GSK3β in the presence and absence of 500 nM Axin. All gel samples were diluted 1:5 to prevent a gel smearing artifact (see Materials and methods).</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig2-figsupp6-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig2-figsupp6-v2.tif"/></fig><fig id="fig2s7" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 7.</label><caption><title>Plots of product vs. time for reaction of pS9-GSK3β with pS45-β-catenin in the presence and absence of Axin.</title><p>(<bold>A</bold>) Product vs. time plots for reactions of pS9-GSK3β with pS45-β-catenin in the absence of Axin. (<bold>B</bold>) Product vs. time plots for reactions of pS9-GSK3β with pS45-β-catenin in the presence of 500 nM Axin. Data in (<bold>A</bold>) and (<bold>B</bold>) correspond to the reaction conditions and western blots shown in <xref ref-type="fig" rid="fig2s6">Figure 2—figure supplement 6</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig2-figsupp7-v2.tif"/></fig><fig id="fig2s8" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 8.</label><caption><title>V<sub>obs</sub> vs. [enzyme].</title><p>V<sub>obs</sub> for fixed concentrations of substrate with varying concentrations of GSK3β or PKA in the presence or absence of Axin. (<bold>A</bold>) Plot of V<sub>obs</sub> vs. [unphosphorylated GSK3β], [pS9-GSK3β], or [GSK3β_S9A] with 50 nM pS45-β-catenin in the presence and absence of 500 nM Axin. V<sub>obs</sub> increases linearly with enzyme concentration, as expected. (<bold>B</bold>) Plot of V<sub>obs</sub> vs. [pS9-GSK3β] with 50 nM pS45-β-catenin in the presence and absence of 500 nM Axin. (<bold>C</bold>) Plot of V<sub>obs</sub> vs. [GSK3β_S9A] with 50 nM pS45-β-catenin in the presence and absence of 500 nM Axin. (<bold>D</bold>) Plot of V<sub>obs</sub> vs. [PKA] with 20 nM GSK3β in the presence and absence of 500 nM Axin_FL or miniAxin. (<bold>E</bold>) Plot of V<sub>obs</sub> vs. [PKA] at 20 nM CREB<sub>127-135</sub> in the presence and absence of 500 nM Axin. Error bars are mean ± SD for at least three biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig2-figsupp8-v2.tif"/></fig><fig id="fig2s9" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 9.</label><caption><title>Recombinant GSK3β is phosphorylated on multiple sites.</title><p>(<bold>A</bold>) Recombinant GSK3β is phosphorylated at phosphosites other than Ser9. Phos-tag gel of GSK3β and GSK3β_S9A with and without treatment with lambda phosphatase. Phos-tag gels were prepared and run as previously described (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>; see Materials and methods). Samples with GSK3β or GSK3β_S9A were prepared in PMP buffer (NEB) with 1 mM MnCl<sub>2</sub> and 400 nM GSK3β or GSK3β_S9A and incubated in the presence or absence of 30 μM lambda phosphatase for 30 min at 30 °C. The slower-migrating species are phosphorylated GSK3β or GSK3β_S9A. The presence of phosphorylated bands in GSK3β_S9A indicates that additional sites besides Ser9 are phosphorylated in recombinant GSK3β. (<bold>B</bold>) Michaelis-Menten plot of <italic>V</italic><sub>obs</sub> versus [pS45-β-catenin] at 10 nM GSK3β_S9A or 10 nM lambda phosphatase-treated GSK3β_S9A. Dephosphorylation of GSK3β_S9A by lambda phosphatase produces an ~5 fold increase in <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub>, largely due to a ~fivefold increase in <italic>k</italic><sub>cat</sub>. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref> for values of fitted kinetic parameters. (<bold>C</bold>) GSK3β kinase activity is affected by phosphorylation state at Ser9 and other phosphosites. Values on arrows are fold-change in <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> for different preparations of GSK3β in reactions with pS45-β-catenin. Dephosphorylation of wt GSK3β or GSK3β _S9A by lambda phosphatase produces ~fivefold increases in <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>). PKA phosphorylation of lambda phosphatase-treated GSK3β to produce pS9-GSK3β leads to a ~200-fold decrease in <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a and e</xref>). PKA phosphorylation of lambda phosphatase-treated GSK3β_S9A produces no effect on <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> because GSK3β_S9A cannot be phosphorylated at the inhibitory Ser9 phosphosite (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>).</p><p><supplementary-material id="fig2s9sdata1"><label>Figure 2—figure supplement 9—source data 1.</label><caption><title>Recombinant GSK3β is phosphorylated on multiple sites.</title><p>Recombinant GSK3β is phosphorylated at phosphosites other than Ser9. Phos-tag gel of GSK3β and GSK3β_S9A with and without treatment with lambda phosphatase. Phos-tag gels were prepared and run as previously described (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>; see Materials and methods). Samples with GSK3β or GSK3β_S9A were prepared in PMP buffer (NEB) with 1 mM MnCl<sub>2</sub> and 400 nM GSK3β or GSK3β_S9A and incubated in the presence or absence of 30 μM lambda phosphatase for 30 min at 30 °C. The slower-migrating species are phosphorylated GSK3β or GSK3β_S9A. The presence of phosphorylated bands in GSK3β_S9A indicates that additional sites besides Ser9 are phosphorylated in recombinant GSK3β.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig2-figsupp9-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig2-figsupp9-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>The scaffold protein Axin cannot overcome pS9-GSK3β inhibition</title><p>Addition of Axin to reactions with unphosphorylated GSK3β and PKA-treated GSK3β_S9A produced modest ~twofold increases in <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> arising from small changes to both <italic>k</italic><sub>cat</sub> and <italic>K</italic><sub>M</sub>, (<xref ref-type="fig" rid="fig3">Figure 3</xref>), consistent with previous results (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). In the pS9-GSK3β reaction, however, Axin produced a ~20-fold <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> increase. Notably, this effect is primarily due to a decrease in the <italic>K</italic><sub>M</sub> to 0.27 µM (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), similar to the values for unphosphorylated GSK3β and GSK3β_S9A (<xref ref-type="fig" rid="fig3">Figure 3B &amp; C</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). This result suggests that Axin can compensate for the inhibitory effect of pS9-GSK3β on substrate binding, possibly because the Axin binding site for β-catenin allows formation of an Axin•GSK3β•β-catenin ternary complex even when the GSK3β priming pocket is blocked.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Axin restores the <italic>K</italic><sub>M</sub> for β-catenin but cannot overcome pS9-GSK3β inactivation.</title><p>(<bold>A–C</bold>) Michaelis-Menten plots of <italic>V</italic><sub>obs</sub> versus [pS45-β-catenin] in the presence and absence of 500 nM Axin with 10 nM pS9-GSK3β (<bold>A</bold>), unphosphorylated GSK3β (<bold>B</bold>) or PKA-treated GSK3β_S9A (<bold>C</bold>). At the Axin concentrations used in these experiments all the GSK3β is bound to Axin (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). (<bold>D</bold>) Minimal kinetic scheme and Michaelis-Menten plots for reactions of GSK3β with pS45-β-catenin in the presence of Axin plotted on the same scale. Values are mean ± SD for at least three biological replicates. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref> for values of fitted kinetic parameters.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Observed rates for data plotted in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85444-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Varying the concentration of Axin does not produce larger rate effects than observed with 500 nM Axin.</title><p>(<bold>A</bold>) Plots of V<sub>obs</sub> vs. [Axin] with 10 nM unphosphorylated GSK3β and 50 nM pS45-β-catenin. (<bold>B</bold>) Plots of V<sub>obs</sub> vs. [Axin] with 10 nM pS9-GSK3β and 50 nM pS45-β-catenin. (<bold>C</bold>) Plots of V<sub>obs</sub> vs. [Axin] with 20 nM PKA and 20 nM GSK3β. Error bars are mean ± SD for at least three biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig3-figsupp1-v2.tif"/></fig></fig-group><p>Although Axin appears to fully rescue the <italic>K</italic><sub>M</sub> effect from Ser9 phosphorylation, there is still a substantial ~10-fold <italic>k</italic><sub>cat</sub> decrease. This behavior is consistent with a non-productive binding model (<xref ref-type="bibr" rid="bib14">Fersht, 1998</xref>), in which Axin assembles a pS9-GSK3β•pS45-β-catenin complex that is still inhibited by pSer9 occupying the priming pocket. In this model, Axin-mediated assembly of the kinase-substrate complex reduces the <italic>K</italic><sub>M</sub>, but this complex cannot react so <italic>k</italic><sub>cat</sub> remains impaired. In cells, if pS9-GSK3β accumulates in the Axin-mediated destruction complex, β-catenin phosphorylation will be inhibited by ~10-fold, likely leading to improper activation of the Wnt pathway. Stimulation with high levels of Wnt ligand produces ~fivefold decreases in GSK3β phosphorylation of β-catenin (<xref ref-type="bibr" rid="bib19">Hannoush, 2008</xref>; <xref ref-type="bibr" rid="bib21">Hernández et al., 2012</xref>), and in vivo changes in β-catenin levels as low as twofold can have measurable effects on transcription of Wnt output genes (<xref ref-type="bibr" rid="bib23">Jacobsen et al., 2016</xref>).</p></sec><sec id="s2-3"><title>Axin prevents accumulation of pS9-GSK3β in the destruction complex</title><p>To test if Axin-bound GSK3β is shielded from upstream kinases, we evaluated the effect of Axin on PKA, a kinase upstream of GSK3β in growth factor signaling (<xref ref-type="bibr" rid="bib13">Fang et al., 2000</xref>). We found that Axin produced a 7-fold drop in <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> for PKA phosphorylation of GSK3β at Ser9, primarily from a fourfold increase in <italic>K</italic><sub>M</sub> (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). This <italic>K</italic><sub>M</sub> increase suggests that Axin interferes with formation of the PKA•GSK3β complex. To determine if this effect is specific to GSK3β, we measured the effect of Axin on the reaction with another PKA substrate, CREB (<xref ref-type="bibr" rid="bib27">Naqvi et al., 2014</xref>). Axin has no effect on observed rates or <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> for the CREB reaction (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). This result indicates that Axin is not a competitive inhibitor of PKA at the concentrations used in our assays, nor is Axin directly binding PKA to regulate its activity.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Axin prevents phosphorylation of GSK3β at Ser9.</title><p>(<bold>A</bold>) Michaelis-Menten plots of <italic>V</italic><sub>obs</sub> versus [GSK3β] with 20 nM PKA in the presence and absence of 500 nM Axin. (<bold>B</bold>) Michaelis-Menten plots of <italic>V</italic><sub>obs</sub> versus [CREB<sub>127-135</sub>] with 20 nM PKA in the presence and absence of 500 nM Axin. Values are mean ± SD for at least three biological replicates. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref> for values of fitted kinetic parameters from (<bold>A</bold>) and (<bold>B</bold>). (<bold>C</bold>) Normalized western blot analysis and blot images of pS9-GSK3β in HEK293 cells transiently expressing Axin or a negative control (see Materials and methods). Normalized pS9-GSK3β levels were calculated for each biological sample by dividing pS9-GSK3β signal by total GSK3β and then averaging across three biological replicates. The p-value between Axin-expressing cells and non-Axin negative control cells is 0.00356 (two-tailed unpaired t-test). Full, uncropped western blot images are shown in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Observed rates for data plotted in <xref ref-type="fig" rid="fig4">Figure 4A and B</xref> and quantification of western blot band intensities for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85444-fig4-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Uncropped western blots for pS9-GSK3β in HEK293 cells.</title><p>Western blot images of pS9-GSK3β and total GSK3β in HEK293 cells transiently expressing Axin or a negative control, related to <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig4-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Representative western blots for the reaction of PKA with GSK3β in the presence and absence of Axin.</title><p>Western blots for reactions of varying concentrations of GSK3β with 20 nM PKA +/-500 nM Axin. 500 nM GSK3β reaction gel samples without Axin were diluted 1:4 to prevent overloading the gel; all other reactions were diluted 1:2 (see Materials and methods). See <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> for quantification.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Representative western blots for the reaction of PKA with GSK3β in the presence and absence of Axin.</title><p>Western blots for reactions of varying concentrations of GSK3β with 20 nM PKA +/-500 nM Axin. 500 nM GSK3β reaction gel samples without Axin were diluted 1:4 to prevent overloading the gel; all other reactions were diluted 1:2 (see Materials and methods).</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig4-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Plots of product vs. time for reaction of PKA with GSK3β in the presence and absence of Axin.</title><p>(<bold>A</bold>) Product vs. time plots for reactions of PKA with GSK3β in the absence of Axin. (<bold>B</bold>) Product vs. time plots for reactions of PKA with GSK3β in the presence of 500 nM Axin. Data in (<bold>A</bold>) and (<bold>B</bold>) correspond to the reaction conditions and western blots shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Uncropped western blots for pS9-GSK3β in HEK293 cells.</title><p>Western blot images of pS9-GSK3β and total GSK3β in HEK293 cells transiently expressing Axin or a negative control.</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Uncropped western blots for pS9-GSK3β in HEK293 cells.</title><p>Western blot images of pS9-GSK3β and total GSK3β in HEK293 cells transiently expressing Axin or a negative control.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85444-fig4-figsupp3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>The Axin peptide is too far from the N-terminus of GSK3β to sterically occlude the Ser9 phosphorylation site.</title><p>(<bold>A</bold>) Schematics of full length Axin, miniAxin, and the minimal Axin peptide used in functional studies. Full length Axin and miniAxin were purified with an N-terminal maltose binding protein (MBP) and a C-terminal His tag. The Axin peptide was expressed as an MBP fusion and cleaved with TEV protease to produce the minimal sequence GS-Axin<sub>381-407</sub>-SGR-His<sub>6</sub> (see Methods). (<bold>B</bold>) Crystal structure of GSK3β in complex with Axin<sub>381-401</sub> (pdb 4nm0, <xref ref-type="bibr" rid="bib36">Stamos et al., 2014</xref>). The GSK3β N-terminal residues 1–25 are not resolved. The Cα-Cα distance from Axin Ile381 to GSK3β Met26 is ~45 Å along the surface of GSK3β, determined by manually plotting five possible paths from Cα-Cα along the surface of GSK3β with distances of 48.1 Å, 44.7 Å, 45.4 Å, 49.9 Å, and 44.3 Å. For example, one path was calculated by measuring and summing the distances between the Cα of Met26 on GSK3β to the Cα of Lys123 on GSK3β and from the Cα of Lys123 on GSK3β to the Cα of Ile381 on Axin. These estimates are likely conservative, as we did not consider steric clash with GSK3β side chains. The direct linear Cα-Cα distance from Axin Ile381 to GSK3β Met26 is 41 Å, but this path sterically clashes with the N-lobe of the kinase. To estimate the distance of ~19 Å from GSK3β Met26 to Ser9, we used a worm-like chain model for a flexible peptide (<xref ref-type="bibr" rid="bib2">Bertagna et al., 2008</xref>). Therefore, the minimal Axin<sub>381-407</sub> peptide is unlikely to sterically occlude access to Ser9. Molecular graphics and analyses performed with UCSF Chimera, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH P41-GM103311 (<xref ref-type="bibr" rid="bib32">Pettersen et al., 2004</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85444-fig4-figsupp4-v2.tif"/></fig></fig-group><p>There are several plausible models for how the Axin•GSK3β interaction might disrupt PKA phosphorylation. The simplest model is that Axin sterically occludes upstream kinases from accessing the Ser9 site on GSK3β. The Axin binding site on GSK3β does not directly overlap with Ser9, nor is it immediately adjacent (<xref ref-type="bibr" rid="bib22">Ikeda et al., 1998</xref>), but Axin is a large, disordered protein and could potentially extend toward the N-terminus of GSK3β. Another possibility is that Axin binding to GSK3β produces allosteric changes that make the GSK3β N-terminus less accessible to upstream kinases.</p><p>To distinguish between these possible models, we first measured the effect of a truncated Axin scaffold on PKA phosphorylation of GSK3β. This miniAxin scaffold (residues 384–518) binds GSK3β with a similar affinity as full-length Axin<sub>1-826</sub> (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). Addition of miniAxin produced a sixfold decrease in <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> with a fourfold increase in <italic>K</italic><sub>M</sub>, similar to full length Axin (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Although miniAxin is substantially smaller than full-length Axin, this construct does not allow us to conclusively rule out a steric blocking mechanism. We therefore expressed a minimal, 27 amino acid peptide, Axin<sub>381-407</sub>, that binds GSK3β (<xref ref-type="bibr" rid="bib20">Hedgepeth et al., 1999</xref>; <xref ref-type="bibr" rid="bib36">Stamos et al., 2014</xref>) and cannot sterically occlude the GSK3β phosphorylation site (<xref ref-type="bibr" rid="bib36">Stamos et al., 2014</xref>; <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). Axin<sub>381-407</sub> produced an eightfold decrease in <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub>, with a sevenfold increase in <italic>K</italic><sub>M</sub>, similar to full length Axin and miniAxin (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). This result supports the model that Axin binding leads to allosteric changes in GSK3β that make it less accessible to PKA.</p><p>One possible structural explanation for the functional data is that the Ser9 phosphorylation site adopts an inaccessible conformation when Axin binds GSK3β. However, Ser9 is located in a flexible N-terminal tail that is unresolved in x-ray crystal structures with or without Axin bound, providing no clear indication for structural changes upon Axin binding (<xref ref-type="bibr" rid="bib11">Dajani et al., 2003</xref>; <xref ref-type="bibr" rid="bib10">Dajani et al., 2001</xref>; <xref ref-type="bibr" rid="bib36">Stamos et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">ter Haar et al., 2001</xref>). An alternative possibility is that the N-terminal tail remains disordered upon Axin binding but adopts altered conformational dynamics that prevent kinase access. Distinct conformational states in intrinsically disordered peptides have been observed previously (<xref ref-type="bibr" rid="bib7">Choi et al., 2011</xref>; <xref ref-type="bibr" rid="bib8">Clouser et al., 2019</xref>). Potentially similar functional behavior has been observed for the activation loop in the MAPK Fus3, which requires the Ste5 scaffold for phosphorylation (<xref ref-type="bibr" rid="bib17">Good et al., 2009</xref>). Free Fus3 is inaccessible to its upstream kinase even though the activation loop is flexible and unresolved in x-ray crystal structures (<xref ref-type="bibr" rid="bib33">Reményi et al., 2005</xref>).</p><p>To determine if Axin prevents pS9-GSK3β accumulation in vivo, we overexpressed Axin in HEK293 cells. In the absence of Axin overexpression, we observed significant basal levels of pS9-GSK3β, in agreement with previous results (<xref ref-type="bibr" rid="bib6">Cantoria et al., 2023</xref>; <xref ref-type="bibr" rid="bib13">Fang et al., 2000</xref>; <xref ref-type="bibr" rid="bib41">Whiting et al., 2015</xref>). When Axin is overexpressed, we observed a significant decrease in pS9-GSK3β levels (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), consistent with our observation that Axin prevents phosphorylation of Ser9 in vitro.</p></sec><sec id="s2-4"><title>Conclusions</title><p>The observation that Axin protects GSK3β from PKA phosphorylation in vitro is consistent with previous in vivo co-immunoprecipitation experiments suggesting that Axin-associated GSK3β is not phosphorylated at Ser9 (<xref ref-type="bibr" rid="bib29">Ng et al., 2009</xref>). Beyond Axin-mediated shielding of GSK3β, other mechanisms could also contribute to preventing accumulation of pS9-GSK3β in the Wnt destruction complex. Axin interacts with the phosphatase PP2A and may promote PP2A-mediated dephosphorylation of pS9-GSK3β (<xref ref-type="bibr" rid="bib6">Cantoria et al., 2023</xref>). Alternatively, subcellular localization or phase separation could sequester GSK3β in distinct pools that are associated with different signaling pathways and independently regulated (<xref ref-type="bibr" rid="bib1">Anton et al., 2022</xref>; <xref ref-type="bibr" rid="bib5">Bock et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Su et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Zhang et al., 2020</xref>). Wnt pathway proteins also phase separate (<xref ref-type="bibr" rid="bib30">Nong et al., 2021</xref>; <xref ref-type="bibr" rid="bib34">Schaefer et al., 2018</xref>), which could exclude kinases like Akt and PKA from accessing Wnt-associated GSK3β. Other components of the destruction complex, such as the accessory scaffold protein APC (<xref ref-type="bibr" rid="bib30">Nong et al., 2021</xref>; <xref ref-type="bibr" rid="bib31">Nusse and Clevers, 2017</xref>), could contribute to these effects. Although these other mechanisms may play an important role, here we have used biochemical reconstitution to systematically evaluate two possible direct contributions of the Axin scaffold to pathway insulation, and our results suggest that Axin can allosterically control the accessibility of GSK3β to upstream signals from competing pathways. These findings provide a biochemical mechanism to explain how scaffold proteins can regulate crosstalk between interconnected cell signaling pathways.</p></sec></sec><sec id="s3" sec-type="materials|methods"><title>Materials and methods</title><sec id="s3-1"><title>Protein expression constructs</title><p>The human Wnt pathway proteins GSK3β, β-catenin, and Axin (hAxin1 isoform 2, Uniprot O15169-2), along with the human CREB<sub>127-135</sub> peptide ILSRRPSYR and mouse PKA were cloned and expressed as previously described (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). All sequences except PKA were cloned into <italic>E. coli</italic> expression vectors containing an N-terminal maltose binding protein (MBP) and a C-terminal His6 tag. The catalytic subunit of mouse PKA was expressed from pET15b with an N-terminal His-tag (addgene #14921) (<xref ref-type="bibr" rid="bib28">Narayana et al., 1997</xref>).</p><p>pS45-β-catenin was produced by coexpression with CK1α, as previously described (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). Lambda phosphatase (λPPase) was cloned with an N-terminal GST tag and a C-terminal His6 tag; the human λPPase sequence was obtained from VMG950 (<xref ref-type="bibr" rid="bib17">Good et al., 2009</xref>). Unphosphorylated GSK3β was produced by coexpression with λPPase. The coexpression plasmid for GSK3β and λPPase was constructed by inserting the GST-λPPase expression cassette (without the His6 tag) into the MBP-GSK3β-His6 plasmid. GSK3β point mutants and Axin truncations were constructed by assembling PCR fragments. Unless otherwise noted, all wt and mutant GSK3β constructs in this work were coexpressed with λPPase to ensure they are unphosphorylated.</p></sec><sec id="s3-2"><title>Protein expression and purification</title><p>For quantitative kinetic and binding assays, all Wnt pathway, CREB, and PKA proteins were expressed in Rosetta (DE3) pLysS <italic>E. coli</italic> cells by inducing with 0.5 mM IPTG overnight at 18 °C. Constructs with N-terminal MBP and C-terminal His6 tags (pS45-β-catenin, Axin, and CREB<sub>127-135</sub>) were affinity purified with HisPur Ni-NTA resin (Thermo Scientific) and amylose resin (NEB). The PKA catalytic subunit was purified on Ni-NTA resin. pS45-β-catenin was produced by coexpression with CK1α, as previously described (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). The Axin peptide, Axin<sub>381-407</sub> was expressed with an N-terminal MBP tag and a C-terminal His tag. The N-terminal MBP tag was removed using TEV protease in an on-bead cleavage during the purification process. Ni-NTA-purified MBP-Axin<sub>381-407</sub> was loaded onto amylose resin, washed with 5 column volumes of amylose wash buffer (20 mM Tris pH 8, 200 mM NaCl, 2 mM βME) and then dialyzed overnight at 4 °C in the presence of 500 nM TEV protease. The solution containing the cleaved peptide was separated from the amylose resin, concentrated, and purified by size exclusion chromatography using a Superdex 75 10/300 GL column (GE Healthcare) to remove TEV protease. Chromatography fractions were monitored by Coomassie-stained SDS-PAGE as the peptide is not detectable by UV. The final purified Axin peptide is GS-Axin<sub>381-407</sub>-SGR-His<sub>6</sub>.</p><p>Unphosphorylated GSK3β and GSK3β_S9A were produced by coexpression with lambda phosphatase and affinity purified with HisPur Ni-NTA resin (Thermo Scientific). Treatment of GSK3β and GSK3β_S9A with lambda phosphatase produces an ~fivefold increase in <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> that is due to an ~fivefold increase in <italic>k</italic><sub>cat</sub> (<xref ref-type="fig" rid="fig2s9">Figure 2—figure supplement 9</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d &amp; e</xref>). To produce PKA-treated pS9-GSK3β and GSK3β_S9A, 10 μM of λPPase-treated, Ni-NTA-purified GSK3β and GSK3β_S9A were incubated with 5 μM PKA and 500 μM ATP for 2 hr at 25 °C. Phosphorylated GSK3β and GSK3β_S9A were separated from PKA by affinity purification with amylose resin (NEB). GSK3β phosphorylation at Ser9 and Tyr216 was assessed by western blot using antibodies for pSer9 GSK3β (Cell Signaling Technology #5558), pTyr216 GSK3β (BD Biosciences #612312), and MBP (Cell Signaling Technology #2396; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). The secondary antibodies were IRDye 800CW Goat Anti-Rabbit IgG antibody (Li-Cor #926–32211) for pSer9 and pTyr216 GSK3β and IRDye 800CW Donkey Anti-Mouse IgG antibody (Li-Cor #926–32212) for MBP. <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref> includes a summary of antibodies used in this work.</p><p>Purified proteins were dialyzed into 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol, and 2 mM DTT at 4 °C, aliquoted and stored at –80 °C. If necessary, proteins were concentrated using 10000 or 30000 MWCO Amicon Ultra-15 Centrifugal Filter devices at 4 °C, 2000×<italic>g</italic>. Protein concentrations were determined using a Bradford assay (Thermo Scientific). pS45-β-catenin was further purified by size exclusion chromatography using a Superdex 200 Increase 10/300 GL column (GE Healthcare) to remove a copurifying fragment before being dialyzed into 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol, and 2 mM DTT, aliquoted, and stored at –80 °C. A Coomassie gel showing the purity of the proteins in this work is shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>.</p></sec><sec id="s3-3"><title>Quantitative kinetic assays</title><p>In vitro kinetic assays were conducted in kinase assay buffer (40 mM HEPES pH 7.4, 50 mM NaCl, 10 mM MgCl<sub>2</sub>, and 0.05% IGEPAL) at 25 °C in 60 µL total volume. Reactions were initiated by adding ATP to a final concentration of 100 µM. This ATP concentration is saturating for all reactions (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). Reaction timepoints for initial rate kinetics were obtained at 10, 30, 60, and 90 s (pS45-β-catenin reactions with unphosphorylated GSK3β and GSK3β_S9A, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplements 4</xref> and <xref ref-type="fig" rid="fig2s5">5</xref>); 1, 2, 5, and 10 min (pS45-β-catenin reactions with pS9-GSK3β, <xref ref-type="fig" rid="fig2s6">Figure 2—figure supplements 6</xref> and <xref ref-type="fig" rid="fig2s7">7</xref>); and 0.5, 1, 2, and 4 min (vary [GSK3β] and [CREB<sub>127-135</sub>] reactions with PKA, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>). Ten µL aliquots were quenched by boiling in 5 X SDS loading buffer. Samples were analyzed by SDS-PAGE and quantitative western blotting as described below (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplements 4</xref>–<xref ref-type="fig" rid="fig2s7">7</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>). For reactions with pS45-β-catenin, all gel samples were diluted fivefold in 1 X SDS loading buffer to prevent a gel smearing artifact that occurs with [pS45-β-catenin]≥500 nM. For reactions with PKA phosphorylation of GSK3β, samples were diluted fourfold (500 nM GSK3β reactions without Axin) or twofold (all other GSK3β concentrations) to prevent signal saturation of the western blot scan.</p><p>GSK3β-phosphorylated β-catenin was detected using a primary anti-Phospho-β-Catenin (Ser33/37/Thr41) antibody (Cell Signaling Technology #9561) that recognizes triply phosphorylated pS33/pS37/pT41-β-catenin (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). PKA-phosphorylated GSK3β was detected using a primary anti-phospho-GSK3β (Ser9) antibody (Cell Signaling Technology #5558) that recognizes pS9-GSK3β (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). PKA-phosphorylated CREB<sub>127-135</sub> was detected using a primary anti-phospho-CREB (Ser133) antibody (Cell Signaling Technology #9198) that recognizes pS133-CREB<sub>127-135</sub> (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). For all reactions, the secondary antibody was IRDye 800CW Goat Anti-Rabbit IgG antibody (Li-Cor #926–32211).</p><p>Concentrations of phosphorylated product in each reaction were determined by comparing western blot signal intensities to an endpoint standard containing 50 nM product phosphorylated to completion (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). For pS45-β-catenin reactions the endpoint is pS45-β-catenin phosphorylated to completion by GSK3β as previously described (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). The pS45-β-catenin standard was prepared in a reaction with 50 nM pS45-β-catenin, 100 nM GSK3β, and 100 µM ATP in kinase assay buffer at 25 °C for 15 min. For PKA phosphorylation of GSK3β reactions the endpoint is pS9-GSK3β, phosphorylated to completion by PKA. The pS9-GSK3β standard was prepared in a reaction with 50 nM unphosphorylated GSK3β, 100 nM PKA, and 500 µM ATP in kinase assay buffer at 25 °C for twenty-four hr. To prevent signal saturation of the western blot scan, the pS9-GSK3β standard was diluted fourfold in 1 x SDS loading dye, to a final concentration of 12.5 nM pS9-GSK3β. For CREB<sub>127-135</sub> reactions the endpoint is pS133-CREB<sub>127-135</sub>, phosphorylated to completion by PKA. The pS133-CREB<sub>127-135</sub> standard was prepared in a reaction with 50 nM CREB<sub>127-135</sub>, 100 nM PKA, and 200 µM ATP in kinase assay buffer at 25 °C for 20 hr.</p><p>Initial rate measurements were obtained from three independent reactions (biological replicates). Phosphorylated product levels from quantitative western blots were analyzed using Image Studio Lite 5.2.5 (Li-Cor) and kinetic parameters were determined by fitting to the Michaelis-Menten equation or to a linear equation using Kaleidagraph 4.1.3. Initial rates for each reaction were determined by fitting a linear model to a graph of [product] vs time. Kinetic parameters were determined by fitting plots of initial rates (<italic>V</italic><sub>obs</sub>) vs. [substrate] to the Michaelis-Menten equation <inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi mathvariant="normal">E</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo>[</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mfenced></mml:math></inline-formula> . Standard errors for <italic>k</italic><sub>cat</sub> and <italic>K</italic><sub>M</sub> reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a – 1e</xref> are from non-linear least squares fits to this equation. Standard errors for <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> were obtained by fitting an alternative form of the equation <inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfenced><mml:msub><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi mathvariant="normal">E</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mo>]</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></inline-formula> . For the pS9-GSK3β reactions without Axin, which did not detectably saturate, the value of <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> was obtained from the slope of linear fit to the plot of <italic>V</italic><sub>obs</sub> vs. [substrate].</p><p>The reaction conditions for in vitro kinetics experiments were tested to confirm the underlying assumptions in the kinetic model. As expected, reaction rates increase linearly with increasing enzyme concentration in all reactions (<xref ref-type="fig" rid="fig2s8">Figure 2—figure supplement 8</xref>). We also identified the optimal scaffold concentration for all reactions (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Scaffold-dependent reactions typically have optimal scaffold concentrations, and can be slow at high concentrations of scaffold protein when kinase and substrate are bound to different scaffolds (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Levchenko et al., 2000</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p></sec><sec id="s3-4"><title>Phos-tag gel analysis of GSK3β phosphorylation</title><p>Phos-tag gels were prepared and run as previously described (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). After electrophoresis, the gel was incubated 3 x with transfer buffer +10 mM EDTA for 10 min before the transfer to increase transfer efficiency. Protein levels were detected with anti-MBP antibody (Cell Signaling Technology #2396; <xref ref-type="fig" rid="fig2s9">Figure 2—figure supplement 9A</xref>). The secondary antibody was IRDye 800CW Donkey Anti-Mouse IgG antibody (Li-Cor #926–32212).</p></sec><sec id="s3-5"><title>Cell lines</title><p>Cell culture experiments were performed with HEK293 cells (ATCC #CRL-1573, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0045">CVCL_0045</ext-link>). Cell cultures were tested monthly for mycoplasma contamination (Southern Biotech #13100–01).</p></sec><sec id="s3-6"><title>In vivo cell culture experiments</title><p>The Axin open reading frame (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>) was cloned into the human expression vector pcDNA3.1(+) (Thermo Fisher) with a C-terminal mCherry tag. For a protein overexpression negative control, mCherry was cloned into the same pcDNA3.1(+) vector. <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref> contains a summary of plasmids used in cell culture experiments.</p><p>HEK293 cells were plated at 5×10<sup>5</sup> cells/mL in 10% FBS DMEM in a 24-well plate. Twenty-four hr after plating, individual wells were transfected with 50 μL Opti-MEM media containing 1 μg DNA and 1.5 μL TurboFectin (Origene TF81001). Twenty-four hr following transfection, cells were starved by replacing media with 1% FBS DMEM. Twenty-four hr after starvation, cells were treated with DMSO (2 μL in 10 mL 1% FBS DMEM). Serum starvation and DMSO treatment were included in our protocol for consistency with previously published experiments (<xref ref-type="bibr" rid="bib6">Cantoria et al., 2023</xref>; <xref ref-type="bibr" rid="bib13">Fang et al., 2000</xref>; <xref ref-type="bibr" rid="bib41">Whiting et al., 2015</xref>). Two hr after DMSO treatment, cells were washed twice with 500 μL PBS and lysed on ice in 40 μL lysis buffer (20 mM TRIS pH 7.5, 30 mM NaCl, 20 mM NaF, 1% NP-40, 0.5% DOC, 0.1% SDS, HALT protease and phosphatase inhibitor mixture [Thermo Scientific #78440]). Lysate was then centrifuged at 13,000×<italic>g</italic> for 10 min at 4 °C. The resulting supernatant was boiled for 10 min in 5 X SDS loading buffer and analyzed by SDS page and quantitative western blotting (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><p>pS9-GSK3β was detected using the same antibody used in kinetics assays (Cell Signaling Technology #5558). Total GSK3β was detected using a primary anti-GSK3β antibody (Cell Signaling Technology #9832). The secondary antibodies were IRDye 800CW Goat Anti-Rabbit IgG antibody (Li-Cor #926–32211) for pS9-GSK3β and IRDye 680RD Donkey Anti-Mouse IgG antibody (Li-Cor #926–68072) for total GSK3β. pS9-GSK3β and total GSK3β levels were analyzed using Image Studio Lite 5.2.5 (Li-Cor).</p></sec><sec id="s3-7"><title>Materials availability statement</title><p>Protein expression plasmids (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>) generated in this work are available from Addgene or upon request.</p></sec></sec></body><back><sec sec-type="additional-information" id="s4"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Supervision, Funding acquisition, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s5"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>For all fitted kinetic parameters, see the Methods section for the kinetic model used to fit the data to obtain observed values of <italic>k</italic><sub>cat</sub>, <italic>K</italic><sub>M</sub>, and <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub>.</title><p>Standard errors are from non-linear least squares fits to the initial rate data as described in the Methods. (<bold>a</bold>) Kinetic parameters for GSK3β reactions with pS45-β-catenin, related to <xref ref-type="fig" rid="fig2">Figures 2</xref>–<xref ref-type="fig" rid="fig3">3</xref>. a See <xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref> for data. The pS9-GSK3β reactions in the absence of Axin did not detectably saturate up to 2 μM substrate (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>), and only the value of <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> could be accurately determined. No deviation from linearity was observed at 2 μM pS45-β-catenin (the highest pS45-β-catenin concentration tested), suggesting a conservative estimate that <italic>K</italic><sub>M</sub> ≥2 μM. pS9-GSK3β, GSK3β, and GSK3β_S9A were coexpressed with lambda phosphatase. pS9-GSK3β and GSK3β_S9A were incubated with PKA and ATP before use (see Methods). The <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> for λPPase-treated GSK3β is ~5 fold higher than for non-λPPase-treated GSK3β used in previous studies (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>) (see <xref ref-type="fig" rid="fig2s9">Figure 2—figure supplement 9C</xref> and e). (<bold>b</bold>) Kinetic parameters for PKA reactions, related to <xref ref-type="fig" rid="fig4">Figure 4</xref>. (<bold>c</bold>) <italic>K</italic><sub>M, ATP</sub> values for all reactions, related to Figure S3. (<bold>d</bold>) Kinetic parameters for pS45-β-catenin reactions with non-PKA treated GSK3β_S9A with and without λPPase treatment, related to <xref ref-type="fig" rid="fig2s9">Figure 2—figure supplement 9</xref>. a λPPase-treated GSK3β_S9A was coexpressed with lambda phosphatase before use (see Methods). Untreated GSK3β_S9A was expressed without lambda phosphatase. (<bold>e</bold>) Values of <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> for untreated, λPPase-treated, and PKA-treated GSK3β and GSK3β_S9A in reactions with the substrate pS45-β-catenin, related to <xref ref-type="fig" rid="fig2s9">Figure 2—figure supplement 9</xref>. a See (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>) and <xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>, and <xref ref-type="fig" rid="fig2s9">Figure 2—figure supplement 9</xref> for data. λPPase-treated GSK3β and GSK3β_S9A were coexpressed with lambda phosphatase before use. PKA-treated GSK3β and GSK3β_S9A were coexpressed with lambda phosphatase and then incubated with PKA and ATP before use (see Methods). PKA-treated GSK3β is pS9-GSK3β. The <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> value for untreated GSK3β is from previous work (<xref ref-type="bibr" rid="bib16">Gavagan et al., 2020</xref>). (<bold>f</bold>) Protein expression plasmids, related to Methods. a All proteins are human sequences except PKA, which is the mouse sequence. b pMBP-MG is a modified version of pMAL-p2X (New England Biolabs) with an N-terminal TEV-cleavable MBP tag and a C-terminal His<sub>6</sub> tag. pBH4 is a modified version of pET15b (Novagen) with an N-terminal TEV-cleavable His<sub>6</sub> tag. pBH4 and pMBP-MG were described previously (<xref ref-type="bibr" rid="bib17">Good et al., 2009</xref>). c pMG024 was constructed by inserting GST from pETARA (<xref ref-type="bibr" rid="bib17">Good et al., 2009</xref>) and the λPPase expression cassette (without the His tag) from pMG026 into the pES001 backbone. The GSK3β_S9A mutant (pMG071) was cloned into this dual expression cassette. d pMG051 was constructed by inserting the GST-CK1α expression cassette (without the His tag) from pMG046 into the pEF019 backbone. (g) Plasmids for cell culture experiments, related to Methods. (<bold>h</bold>) Antibodies, related to Methods.</p></caption><media xlink:href="elife-85444-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85444-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Tables of data plotted in supplemental figures.</title></caption><media xlink:href="elife-85444-data1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s6"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 2-4 and supplemental figures.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dustin Maly, John Scott, Maryanne Kihiu and members of the Zalatan group for comments and discussion. This work was supported by NIH R35 GM124773 (JGZ).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anton</surname><given-names>SE</given-names></name><name><surname>Kayser</surname><given-names>C</given-names></name><name><surname>Maiellaro</surname><given-names>I</given-names></name><name><surname>Nemec</surname><given-names>K</given-names></name><name><surname>Möller</surname><given-names>J</given-names></name><name><surname>Koschinski</surname><given-names>A</given-names></name><name><surname>Zaccolo</surname><given-names>M</given-names></name><name><surname>Annibale</surname><given-names>P</given-names></name><name><surname>Falcke</surname><given-names>M</given-names></name><name><surname>Lohse</surname><given-names>MJ</given-names></name><name><surname>Bock</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Receptor-associated independent cAMP nanodomains mediate spatiotemporal specificity of GPCR signaling</article-title><source>Cell</source><volume>185</volume><fpage>1130</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.02.011</pub-id><pub-id pub-id-type="pmid">35294858</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertagna</surname><given-names>A</given-names></name><name><surname>Toptygin</surname><given-names>D</given-names></name><name><surname>Brand</surname><given-names>L</given-names></name><name><surname>Barrick</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The effects of conformational heterogeneity on the binding of the Notch intracellular domain to effector proteins: a case of biologically tuned disorder</article-title><source>Biochemical Society Transactions</source><volume>36</volume><fpage>157</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1042/BST0360157</pub-id><pub-id pub-id-type="pmid">18363556</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beurel</surname><given-names>E</given-names></name><name><surname>Grieco</surname><given-names>SF</given-names></name><name><surname>Jope</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases</article-title><source>Pharmacology &amp; Therapeutics</source><volume>148</volume><fpage>114</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.11.016</pub-id><pub-id pub-id-type="pmid">25435019</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>RV</given-names></name><name><surname>Andersson</surname><given-names>U</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Knerr</surname><given-names>L</given-names></name><name><surname>Bauer</surname><given-names>U</given-names></name><name><surname>Sundgren-Andersson</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The conundrum of GSK3 inhibitors: Is it the dawn of a new beginning?</article-title><source>Journal of Alzheimer’s Disease</source><volume>64</volume><fpage>S547</fpage><lpage>S554</lpage><pub-id pub-id-type="doi">10.3233/JAD-179934</pub-id><pub-id pub-id-type="pmid">29758944</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bock</surname><given-names>A</given-names></name><name><surname>Annibale</surname><given-names>P</given-names></name><name><surname>Konrad</surname><given-names>C</given-names></name><name><surname>Hannawacker</surname><given-names>A</given-names></name><name><surname>Anton</surname><given-names>SE</given-names></name><name><surname>Maiellaro</surname><given-names>I</given-names></name><name><surname>Zabel</surname><given-names>U</given-names></name><name><surname>Sivaramakrishnan</surname><given-names>S</given-names></name><name><surname>Falcke</surname><given-names>M</given-names></name><name><surname>Lohse</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Optical mapping of cAMP signaling at the nanometer scale</article-title><source>Cell</source><volume>182</volume><fpage>1519</fpage><lpage>1530</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.07.035</pub-id><pub-id pub-id-type="pmid">32846156</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantoria</surname><given-names>MJ</given-names></name><name><surname>Alizadeh</surname><given-names>E</given-names></name><name><surname>Ravi</surname><given-names>J</given-names></name><name><surname>Varghese</surname><given-names>RP</given-names></name><name><surname>Bunnag</surname><given-names>N</given-names></name><name><surname>Pond</surname><given-names>KW</given-names></name><name><surname>Kettenbach</surname><given-names>AN</given-names></name><name><surname>Ahmed</surname><given-names>Y</given-names></name><name><surname>Paek</surname><given-names>AL</given-names></name><name><surname>Tyson</surname><given-names>JJ</given-names></name><name><surname>Doubrovinski</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Thorne</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Feedback in the β-catenin destruction complex imparts bistability and cellular memory</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2208787120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2208787120</pub-id><pub-id pub-id-type="pmid">36598937</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>UB</given-names></name><name><surname>McCann</surname><given-names>JJ</given-names></name><name><surname>Weninger</surname><given-names>KR</given-names></name><name><surname>Bowen</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Beyond the random coil: stochastic conformational switching in intrinsically disordered proteins</article-title><source>Structure</source><volume>19</volume><fpage>566</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.str.2011.01.011</pub-id><pub-id pub-id-type="pmid">21481779</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clouser</surname><given-names>AF</given-names></name><name><surname>Baughman</surname><given-names>HE</given-names></name><name><surname>Basanta</surname><given-names>B</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Klevit</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interplay of disordered and ordered regions of a human small heat shock protein yields an ensemble of “quasi-ordered” states</article-title><source>eLife</source><volume>8</volume><elocation-id>e50259</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.50259</pub-id><pub-id pub-id-type="pmid">31573509</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>DAE</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Andjelkovich</surname><given-names>M</given-names></name><name><surname>Hemmings</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</article-title><source>Nature</source><volume>378</volume><fpage>785</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1038/378785a0</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dajani</surname><given-names>R</given-names></name><name><surname>Fraser</surname><given-names>E</given-names></name><name><surname>Roe</surname><given-names>SM</given-names></name><name><surname>Young</surname><given-names>N</given-names></name><name><surname>Good</surname><given-names>V</given-names></name><name><surname>Dale</surname><given-names>TC</given-names></name><name><surname>Pearl</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition</article-title><source>Cell</source><volume>105</volume><fpage>721</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(01)00374-9</pub-id><pub-id pub-id-type="pmid">11440715</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dajani</surname><given-names>R</given-names></name><name><surname>Fraser</surname><given-names>E</given-names></name><name><surname>Roe</surname><given-names>SM</given-names></name><name><surname>Yeo</surname><given-names>M</given-names></name><name><surname>Good</surname><given-names>VM</given-names></name><name><surname>Thompson</surname><given-names>V</given-names></name><name><surname>Dale</surname><given-names>TC</given-names></name><name><surname>Pearl</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex</article-title><source>The EMBO Journal</source><volume>22</volume><fpage>494</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg068</pub-id><pub-id pub-id-type="pmid">12554650</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>VW</given-names></name><name><surname>Chen</surname><given-names>RH</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>32475</fpage><lpage>32481</lpage><pub-id pub-id-type="doi">10.1074/jbc.M005342200</pub-id><pub-id pub-id-type="pmid">10913153</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>SX</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Bast</surname><given-names>RC</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A</article-title><source>PNAS</source><volume>97</volume><fpage>11960</fpage><lpage>11965</lpage><pub-id pub-id-type="doi">10.1073/pnas.220413597</pub-id><pub-id pub-id-type="pmid">11035810</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fersht</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><source>Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding</source><publisher-name>W.H. Freeman and Company</publisher-name></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frame</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>GSK3 takes centre stage more than 20 years after its discovery</article-title><source>The Biochemical Journal</source><volume>359</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1042/0264-6021:3590001</pub-id><pub-id pub-id-type="pmid">11563964</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavagan</surname><given-names>M</given-names></name><name><surname>Fagnan</surname><given-names>E</given-names></name><name><surname>Speltz</surname><given-names>EB</given-names></name><name><surname>Zalatan</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The scaffold protein axin promotes signaling specificity within the wnt pathway by suppressing competing kinase reactions</article-title><source>Cell Systems</source><volume>10</volume><fpage>515</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2020.05.002</pub-id><pub-id pub-id-type="pmid">32553184</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Good</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Singleton</surname><given-names>J</given-names></name><name><surname>Reményi</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The Ste5 scaffold directs mating signaling by catalytically unlocking the Fus3 MAP kinase for activation</article-title><source>Cell</source><volume>136</volume><fpage>1085</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.049</pub-id><pub-id pub-id-type="pmid">19303851</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Good</surname><given-names>MC</given-names></name><name><surname>Zalatan</surname><given-names>JG</given-names></name><name><surname>Lim</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Scaffold proteins: hubs for controlling the flow of cellular information</article-title><source>Science</source><volume>332</volume><fpage>680</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1126/science.1198701</pub-id><pub-id pub-id-type="pmid">21551057</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannoush</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Kinetics of Wnt-driven beta-catenin stabilization revealed by quantitative and temporal imaging</article-title><source>PLOS ONE</source><volume>3</volume><elocation-id>e3498</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0003498</pub-id><pub-id pub-id-type="pmid">18941539</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedgepeth</surname><given-names>CM</given-names></name><name><surname>Deardorff</surname><given-names>MA</given-names></name><name><surname>Rankin</surname><given-names>K</given-names></name><name><surname>Klein</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin</article-title><source>Molecular and Cellular Biology</source><volume>19</volume><fpage>7147</fpage><lpage>7157</lpage><pub-id pub-id-type="doi">10.1128/MCB.19.10.7147</pub-id><pub-id pub-id-type="pmid">10490650</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández</surname><given-names>AR</given-names></name><name><surname>Klein</surname><given-names>AM</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Kinetic responses of β-catenin specify the sites of Wnt control</article-title><source>Science</source><volume>338</volume><fpage>1337</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1126/science.1228734</pub-id><pub-id pub-id-type="pmid">23138978</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>S</given-names></name><name><surname>Kishida</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Murai</surname><given-names>H</given-names></name><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Kikuchi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin</article-title><source>The EMBO Journal</source><volume>17</volume><fpage>1371</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.5.1371</pub-id><pub-id pub-id-type="pmid">9482734</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Heijmans</surname><given-names>N</given-names></name><name><surname>Verkaar</surname><given-names>F</given-names></name><name><surname>Smit</surname><given-names>MJ</given-names></name><name><surname>Heringa</surname><given-names>J</given-names></name><name><surname>van Amerongen</surname><given-names>R</given-names></name><name><surname>Feenstra</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Construction and experimental validation of a petri net model of Wnt/β-Catenin signaling</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0155743</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0155743</pub-id><pub-id pub-id-type="pmid">27218469</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>J</given-names></name><name><surname>Brennesvik</surname><given-names>EO</given-names></name><name><surname>Lai</surname><given-names>YC</given-names></name><name><surname>Shepherd</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>GSK-3beta regulation in skeletal muscles by adrenaline and insulin: evidence that PKA and PKB regulate different pools of GSK-3</article-title><source>Cellular Signalling</source><volume>19</volume><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2006.06.006</pub-id><pub-id pub-id-type="pmid">16934435</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levchenko</surname><given-names>A</given-names></name><name><surname>Bruck</surname><given-names>J</given-names></name><name><surname>Sternberg</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Scaffold proteins may biphasically affect the levels of mitogen-activated protein kinase signaling and reduce its threshold properties</article-title><source>PNAS</source><volume>97</volume><fpage>5818</fpage><lpage>5823</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.11.5818</pub-id><pub-id pub-id-type="pmid">10823939</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McManus</surname><given-names>EJ</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Armit</surname><given-names>LJ</given-names></name><name><surname>Ronaldson</surname><given-names>L</given-names></name><name><surname>Shpiro</surname><given-names>N</given-names></name><name><surname>Marquez</surname><given-names>R</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis</article-title><source>The EMBO Journal</source><volume>24</volume><fpage>1571</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600633</pub-id><pub-id pub-id-type="pmid">15791206</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naqvi</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>KJ</given-names></name><name><surname>Arthur</surname><given-names>JSC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CREB phosphorylation at Ser133 regulates transcription via distinct mechanisms downstream of cAMP and MAPK signalling</article-title><source>The Biochemical Journal</source><volume>458</volume><fpage>469</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1042/BJ20131115</pub-id><pub-id pub-id-type="pmid">24438093</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayana</surname><given-names>N</given-names></name><name><surname>Cox</surname><given-names>S</given-names></name><name><surname>Shaltiel</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Xuong</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of cAMP-dependent protein kinase complexed with the peptide inhibitor PKI(5-24) and adenosine</article-title><source>Biochemistry</source><volume>36</volume><fpage>4438</fpage><lpage>4448</lpage><pub-id pub-id-type="doi">10.1021/bi961947+</pub-id><pub-id pub-id-type="pmid">9109651</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>SS</given-names></name><name><surname>Mahmoudi</surname><given-names>T</given-names></name><name><surname>Danenberg</surname><given-names>E</given-names></name><name><surname>Bejaoui</surname><given-names>I</given-names></name><name><surname>de Lau</surname><given-names>W</given-names></name><name><surname>Korswagen</surname><given-names>HC</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>35308</fpage><lpage>35313</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.078261</pub-id><pub-id pub-id-type="pmid">19850932</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nong</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>YG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Phase separation of Axin organizes the β-catenin destruction complex</article-title><source>The Journal of Cell Biology</source><volume>220</volume><elocation-id>e202012112</elocation-id><pub-id pub-id-type="doi">10.1083/jcb.202012112</pub-id><pub-id pub-id-type="pmid">33651074</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Wnt/β-Catenin signaling, disease, and emerging therapeutic modalities</article-title><source>Cell</source><volume>169</volume><fpage>985</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.016</pub-id><pub-id pub-id-type="pmid">28575679</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF Chimera--A visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reményi</surname><given-names>A</given-names></name><name><surname>Good</surname><given-names>MC</given-names></name><name><surname>Bhattacharyya</surname><given-names>RP</given-names></name><name><surname>Lim</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The role of docking interactions in mediating signaling input, output, and discrimination in the yeast MAPK network</article-title><source>Molecular Cell</source><volume>20</volume><fpage>951</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2005.10.030</pub-id><pub-id pub-id-type="pmid">16364919</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>KN</given-names></name><name><surname>Bonello</surname><given-names>TT</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>CE</given-names></name><name><surname>Roberts</surname><given-names>DM</given-names></name><name><surname>McKay</surname><given-names>DJ</given-names></name><name><surname>Peifer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Supramolecular assembly of the beta-catenin destruction complex and the effect of Wnt signaling on its localization, molecular size, and activity in vivo</article-title><source>PLOS Genetics</source><volume>14</volume><elocation-id>e1007339</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007339</pub-id><pub-id pub-id-type="pmid">29641560</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stambolic</surname><given-names>V</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation</article-title><source>The Biochemical Journal</source><volume>303</volume><fpage>701</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1042/bj3030701</pub-id><pub-id pub-id-type="pmid">7980435</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamos</surname><given-names>JL</given-names></name><name><surname>Chu</surname><given-names>MLH</given-names></name><name><surname>Enos</surname><given-names>MD</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6</article-title><source>eLife</source><volume>3</volume><elocation-id>e01998</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.01998</pub-id><pub-id pub-id-type="pmid">24642411</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Ditlev</surname><given-names>JA</given-names></name><name><surname>Hui</surname><given-names>E</given-names></name><name><surname>Xing</surname><given-names>W</given-names></name><name><surname>Banjade</surname><given-names>S</given-names></name><name><surname>Okrut</surname><given-names>J</given-names></name><name><surname>King</surname><given-names>DS</given-names></name><name><surname>Taunton</surname><given-names>J</given-names></name><name><surname>Rosen</surname><given-names>MK</given-names></name><name><surname>Vale</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Phase separation of signaling molecules promotes T cell receptor signal transduction</article-title><source>Science</source><volume>352</volume><fpage>595</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1126/science.aad9964</pub-id><pub-id pub-id-type="pmid">27056844</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>C</given-names></name><name><surname>Leighton</surname><given-names>IA</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling</article-title><source>The Biochemical Journal</source><volume>296 (Pt 1)</volume><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1042/bj2960015</pub-id><pub-id pub-id-type="pmid">8250835</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>What are the bona fide GSK3 substrates?</article-title><source>International Journal of Alzheimer’s Disease</source><volume>2011</volume><elocation-id>505607</elocation-id><pub-id pub-id-type="doi">10.4061/2011/505607</pub-id><pub-id pub-id-type="pmid">21629754</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ter Haar</surname><given-names>E</given-names></name><name><surname>Coll</surname><given-names>JT</given-names></name><name><surname>Austen</surname><given-names>DA</given-names></name><name><surname>Hsiao</surname><given-names>HM</given-names></name><name><surname>Swenson</surname><given-names>L</given-names></name><name><surname>Jain</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Structure of GSK3beta reveals a primed phosphorylation mechanism</article-title><source>Nature Structural Biology</source><volume>8</volume><fpage>593</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1038/89624</pub-id><pub-id pub-id-type="pmid">11427888</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiting</surname><given-names>JL</given-names></name><name><surname>Nygren</surname><given-names>PJ</given-names></name><name><surname>Tunquist</surname><given-names>BJ</given-names></name><name><surname>Langeberg</surname><given-names>LK</given-names></name><name><surname>Seternes</surname><given-names>OM</given-names></name><name><surname>Scott</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Protein Kinase A opposes the phosphorylation-dependent recruitment of glycogen synthase kinase 3β to A-kinase anchoring protein 220</article-title><source>The Journal of Biological Chemistry</source><volume>290</volume><fpage>19445</fpage><lpage>19457</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.654822</pub-id><pub-id pub-id-type="pmid">26088133</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JZ</given-names></name><name><surname>Lu</surname><given-names>TW</given-names></name><name><surname>Stolerman</surname><given-names>LM</given-names></name><name><surname>Tenner</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>JF</given-names></name><name><surname>Falcke</surname><given-names>M</given-names></name><name><surname>Rangamani</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Phase separation of a PKA regulatory subunit controls cAMP compartmentation and oncogenic signaling</article-title><source>Cell</source><volume>182</volume><fpage>1531</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.07.043</pub-id><pub-id pub-id-type="pmid">32846158</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85444.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jura</surname><given-names>Natalia</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05t99sp05</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.12.05.519208" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.12.05.519208"/></front-stub><body><p>This study presents a valuable and elegant kinetic analysis of the GSKbeta activity as a function of phosphorylation and Axin binding - providing insights into critical steps of Wnt pathway signaling. The results will be of big use to the broader signaling community. The work will be of broad interest to cell biologists and biochemists.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85444.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Jura</surname><given-names>Natalia</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05t99sp05</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.12.05.519208">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.12.05.519208v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>[Editors’ note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.]</p><p>Thank you for submitting the paper &quot;The Axin scaffold protects the kinase GSK3β from cross-pathway inhibition&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous.</p><p>Comments to the Authors:</p><p>We are sorry to say that, after consultation with the reviewers, we have decided that this work will not be considered for publication by <italic>eLife</italic> within its current scope. Both reviewers agree that the elegant kinetics analysis of GSKb activity as a function of phosphorylation and Axin binding is thorough and will be very useful for the broader scientific community. However, the main criticism shared by the reviewers, is that the study does not present a big conceptual advance in mechanistic understanding of how the Axin scaffold shields GSKb from phosphorylation and contributes to the insulation of this kinase from other activating stimuli. If you are confident that such evidence could be provided within the revisions time frame, <italic>eLife</italic> would welcome the resubmission and will do its best to send the revised manuscript for assessment to the same reviewers. However, if such evidence cannot be provided in a reasonable time frame, we encourage you to submit your study for consideration for publication in a more specialized journal.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>– At the start of the Results section and in Figure 2, the definitions of kCAT and Km should be given in a bit more detail (at present the reader is only provided with a reference to the 2020 paper). This will make the story a bit easier to read for non-biochemists. For example, lines 106-109 are not intuitive to follow.</p><p>– The added value of the kinetic schemes in each of the figure panels is unclear as the link to specific biological/signal transduction steps is not made clear.</p><p>– The cartoons in Figure 1 could also be improved to clarify the questions/knowledge gaps and specific mechanistic options.</p><p>– The authors convincingly show that AXIN1 can play a role in shielding GSK3 from auto- inhibition. As it stands, the impact of this work on the field of WNT/CTNNB1 signaling is likely to remain limited. This is mainly due to the reason that the mechanism by which AXIN1 shields the WNT/CTNNB1 signaling pool of GSK3 from pSer9 inhibition remains unresolved. Based on the fact that a mini AXIN1 (i.e. an AXIN1 fragment) behaves the same as WT AXIN1, the authors conclude that AXIN1 likely causes allosteric changes on GSK3 but is less likely to block PKA from binding. They cannot conclusively show this, however, as they do not have evidence in favour of one or the other explanation.</p><p>– The impact of this work would be greater if the authors could indeed discriminate between the two possible mechanisms they present (allosteric changes on GSK3 or blocking the binding of PKA).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85444.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>[Editors’ note: The authors appealed the original decision. What follows is the authors’ response to the first round of review.]</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>– At the start of the Results section and in Figure 2, the definitions of kCAT and Km should be given in a bit more detail (at present the reader is only provided with a reference to the 2020 paper). This will make the story a bit easier to read for non-biochemists. For example, lines 106-109 are not intuitive to follow.</p></disp-quote><p>We have added additional explanation of the significance of <italic>k</italic><sub>cat</sub> and <italic>K</italic><sub>M</sub> values at the start of the Results section (lines 61-62). We have also added content and a reference to clarify lines 106-109 (now lines 83-86). Given the space restrictions for the Short Report format our explanations are brief, we request editorial guidance if further elaboration is necessary.</p><disp-quote content-type="editor-comment"><p>– The added value of the kinetic schemes in each of the figure panels is unclear as the link to specific biological/signal transduction steps is not made clear.</p></disp-quote><p>Kinetic schemes are included with each figure panel to enable clear comparisons between different reactions. We appreciate the reviewer’s point that it would be helpful to connect each scheme to a biological step, but we suggest that significant space would be necessary to place each reaction in a biological context and would largely reproduce information that is available in Figure 1.</p><disp-quote content-type="editor-comment"><p>– The cartoons in Figure 1 could also be improved to clarify the questions/knowledge gaps and specific mechanistic options.</p></disp-quote><p>We have added a panel to Figure 1 to clarify the mechanistic models and we have corrected a mistake that was noted by Reviewer #2. We would be happy to further revise the figure if the editors or reviewers have additional suggestions.</p><disp-quote content-type="editor-comment"><p>– The authors convincingly show that AXIN1 can play a role in shielding GSK3 from auto- inhibition. As it stands, the impact of this work on the field of WNT/CTNNB1 signaling is likely to remain limited. This is mainly due to the reason that the mechanism by which AXIN1 shields the WNT/CTNNB1 signaling pool of GSK3 from pSer9 inhibition remains unresolved. Based on the fact that a mini AXIN1 (i.e. an AXIN1 fragment) behaves the same as WT AXIN1, the authors conclude that AXIN1 likely causes allosteric changes on GSK3 but is less likely to block PKA from binding. They cannot conclusively show this, however, as they do not have evidence in favour of one or the other explanation.</p></disp-quote><p>We thank the reviewer for this important comment which details the central concern raised in the review process. To address this point, we have collected additional biochemical data that conclusively shows that the Axin shielding effect is allosteric and not a steric block. We demonstrated that a minimal, 27 amino acid Axin peptide produces the same GSK3β shielding behavior as full length Axin and miniAxin. The minimal Axin peptide does not sterically occlude the GSK3β phosphorylation site. This data is included in a revised Fig 4A and described on lines 151-157 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>– The impact of this work would be greater if the authors could indeed discriminate between the two possible mechanisms they present (allosteric changes on GSK3 or blocking the binding of PKA).</p></disp-quote><p>We agree with the reviewer on this central point and have conducted additional experiments that conclusively resolve the issue. These experiments are described above and included in the revised manuscript (Figure 4A, lines 115-120).</p></body></sub-article></article>